OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical Immunology is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
APDS patients with immune-complex vasculitis and resolution with leniolisib	876022323
Understanding the pathogenic significance of altered calcium-calmodulin signaling in T cells in autoimmune diseases	825505844
COVID-19 pathophysiology: A review	1279
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China	920
COVID-19: Immunology and treatment options	445
Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases	403
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101	235
Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy	208
Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients	197
Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic	184
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy	179
COVID-19: A review of therapeutic strategies and vaccine candidates	169
Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to “potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in aut	150
Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients	122
The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives	122
Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19	118
Type 3 hypersensitivity in COVID-19 vasculitis	114
The IL-2 – IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptor	113
COVID-19 pneumonia: CD8+ T and NK cells are decreased in number but compensatory increased in cytotoxic potential	113
On the molecular determinants of the SARS-CoV-2 attack	109
Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine	103
Interrelations between COVID-19 and other disorders	100
Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19	98
Influenza infection, SARS, MERS and COVID-19: Cytokine storm – The common denominator and the lessons to be learned	96
Recent advances on signaling pathways and their inhibitors in rheumatoid arthritis	87

Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19	80
Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!	80
SARS-CoV-2 infections in children and young people	80
Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study	80
Comorbidities associated with psoriatic arthritis: Review and update	79
Possible role of HLA class-I genotype in SARS-CoV-2 infection and progression: A pilot study in a cohort of Covid-19 Spanish patients	75
Micronutrients as immunomodulatory tools for COVID-19 management	74
Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment	66
Treating COVID-19 with colchicine in community healthcare setting	65
Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine	59
Complex syndromes of chronic pain, fatigue and cognitive impairment linked to autoimmune dysautonomia and small fiber neuropathy	57
Characterization of PANoptosis patterns predicts survival and immunotherapy response in gastric cancer	51
Laboratory biomarkers associated with COVID-19 severity and management	50
COVID-19 in a patient with long-term use of glucocorticoids: A study of a familial cluster	46
Covid-19 vaccine and autoimmunity: Awakening the sleeping dragon	45
Genetic justification of severe COVID-19 using a rigorous algorithm	45
Development of child immunity in the context of COVID-19 pandemic	44
Galectin-3 regulates microglial activation and promotes inflammation through TLR4/MyD88/NF-kB in experimental autoimmune uveitis	43